February 6, 2026
Pills, thrills, and coupon spills
White House launches direct-to-consumer drug site TrumpRx
Bargain miracle or “Trump University” 2.0? Internet roasts and defends TrumpRx coupon hub
TLDR: Trump launched TrumpRx, a government-run hub that points shoppers to drugmaker discounts, aiming to cut costs for cash-paying patients. Commenters are split between calling it a “coupon middleman” or a helpful win for the uninsured, with a viral math flub and Mark Cuban watch fueling the drama.
Trump unveiled TrumpRx with a promise to slash drug prices, but the internet immediately split into two loud camps. The site isn’t a pharmacy; it’s a coupon hub that sends people to drugmakers’ own pages (think Lilly’s weight‑loss shot Zepbound) or hands out discount codes for the pharmacy. Supporters say it could finally give uninsured and under‑insured patients a break. Skeptics say it’s just more middlemen with a fresh coat of paint.
The snark hit fast. One top quip: “Is this like Trump University?” Others zeroed in on a viral screenshot where a touted price drop was… mathematically challenged. “$1,449 → $252 is ‘93% off,’ apparently?” they jeered. Meanwhile policy‑minded commenters argued if you’ve got insurance, these cash deals may not count toward your deductible—so what’s the point? Free‑market diehards demanded the “real fix”: let Americans buy meds from other countries, period.
There’s drama around what’s actually on offer, too. At launch, only five companies (AstraZeneca, Lilly, EMD Serono, Novo Nordisk, Pfizer) appear, with more “coming soon.” An expert from health policy group KFF warned this isn’t a one‑and‑done solution for everyone. Still, some see a silver lining for drugs that insurers rarely cover—like obesity meds. The wildcard? What does Mark Cuban, king of Cost Plus Drugs, think. The crowd’s waiting for that take like it’s the season finale.
Key Points
- •The White House launched TrumpRx, a government website that aggregates manufacturer discounts and pharmacy coupons for prescription drugs.
- •TrumpRx targets cash-paying consumers and directs them to drugmakers’ direct-to-consumer platforms; it does not sell medications directly.
- •At launch, medicines are listed from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, with more companies to be added.
- •The platform is tied to pricing agreements under a “most favored nation” policy and includes discounts for Medicaid patients.
- •Experts say the site may benefit uninsured or underinsured patients, while insured users may see limited advantage and purchases may not count toward deductibles or out-of-pocket maximums.